Opinion|Videos|September 10, 2024
HMA Persistence and Effectiveness in Higher Risk MDS
Medical experts offer insights on the persistence and effectiveness of HMAs in patients with higher-risk MDS.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What insights do you have on the persistence and effectiveness of hypomethylating agents in patients with higher-risk myelodysplastic syndromes, and how do these data inform treatment decisions?
- Please include a discussion of 65th American Society of Hematology Annual Meeting and Exposition abstract 548 by Zeidan et al.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Multiagonists Outpace Older GLP-1 Drugs for Weight Loss
2
Physical Function Views Differ Between Older AML Patients, Clinicians
3
Evolocumab Cuts Death Risk for a First Heart Attack or Stroke
4
Better Cardiovascular Health Tied to Lower Overactive Bladder Risk
5